EYPT - EyePoint Pharmaceuticals Inc Stock Price, Fair Value and News

$7.10-0.02 (-0.28%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

EYPT Price Action

Last 7 days

-4.8%

Last 30 days

-20.8%

Last 90 days

-20.3%

Trailing 12 Months

-65.8%

EYPT RSI Chart

EYPT Valuation

Market Cap

484.6M

Price/Earnings (Trailing)

-4.68

Price/Sales (Trailing)

10.6

EV/EBITDA

-10.18

Price/Free Cashflow

-4.11

EYPT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

EYPT Fundamentals

EYPT Revenue

Revenue (TTM)

45.7M

Rev. Growth (Yr)

-30.77%

Rev. Growth (Qtr)

11.05%

EYPT Earnings

Earnings (TTM)

-103.6M

Earnings Growth (Yr)

-132.8%

Earnings Growth (Qtr)

4.75%

EYPT Profitability

EBT Margin

-154.69%

Return on Equity

-47.35%

Return on Assets

-34.42%

Free Cashflow Yield

-24.36%

EYPT Investor Care

Shares Dilution (1Y)

93.29%

Diluted EPS (TTM)

-1.99

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	50.0M	50.4M	45.7M	0
2023	39.8M	37.3M	42.5M	46.0M
2022	38.9M	41.5M	42.4M	41.4M
2021	34.3M	39.2M	32.5M	36.9M
2020	25.8M	22.8M	35.9M	34.4M
2019	5.7M	12.2M	14.2M	20.4M
2018	2.9M	3.0M	3.1M	4.6M
2017	6.1M	7.5M	7.6M	2.6M
2016	7.9M	1.6M	3.1M	4.6M
2015	26.4M	26.6M	20.3M	14.1M
2014	3.7M	3.5M	28.2M	28.1M
2013	2.4M	2.1M	2.2M	2.2M
2012	6.5M	3.5M	2.4M	2.4M
2011	9.5M	5.0M	6.1M	6.4M
2010	0	23.1M	18.5M	14.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals, Inc. focuses on developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The company's pipeline leverages its proprietary erodible Durasert E technology for sustained intraocular drug delivery, including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment, which is in Phase 2 clinical trials. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Jay S. Duker M.D.
WEBSITE	https://eyepointpharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	144

EyePoint Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for EyePoint Pharmaceuticals Inc? What does EYPT stand for in stocks?

EYPT is the stock ticker symbol of EyePoint Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of EyePoint Pharmaceuticals Inc (EYPT)?

As of Fri Dec 20 2024, market cap of EyePoint Pharmaceuticals Inc is 484.58 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EYPT stock?

You can check EYPT's fair value in chart for subscribers.

Is EyePoint Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether EYPT is over valued or under valued. Whether EyePoint Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact EyePoint Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EYPT.

What is EyePoint Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, EYPT's PE ratio (Price to Earnings) is -4.68 and Price to Sales (PS) ratio is 10.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EYPT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on EyePoint Pharmaceuticals Inc's stock?

In the past 10 years, EyePoint Pharmaceuticals Inc has provided -0.159 (multiply by 100 for percentage) rate of return.